Finally, the clinical and therapeutic approaches of lung cancer have had great advances over the last few decades by means of translational studies that identified predictive biomarkers already established in clinical practice, such as the of EGFR mutation and the of ALK-EML4 fusion. This evidence concerns the gene EML4 and lung carcinoma.